PerkinElmer
check quantity

PD-L1 (human) AlphaLISA Detection Kit, 100 assay points

The AlphaLISA® Human PD-L1 Detection Kit is designed for detection and quantitation of Human PD-L1 (CD274/B7-H1) in immunoassay buffer, human serum, plasma, and cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps).

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Part Number Unit Size List Price Your Price Quantity
AL355HV 100 assay points 436.00 GBP
AL355C 500 assay points 926.00 GBP
AL355F 5,000 assay points 6110.00 GBP

You successfully added item(s) to your cart

Overview

Formats:

  • Our HV (100 assay point) kits allow you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. Human PD-L1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. PD-L1, together with PD-L2, are two ligands for PD-1 (programmed death 1), a member of the CD28 family of immunoreceptors. By binding to PD-1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Disclaimer:  For research use only. Not for use in diagnostic procedures.

Specifications

Assay Target PD-L1
Assay Target Class Protein
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Cancer
Unit Size 100 assay points

Resources, Events & More

Resource Type File Name File Format
Brochure Alpha product listing PDF 132 KB
Application Note Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA PDF 4 MB
Data Sheet AlphaLISA human PD-L1 Detection Kit PDF 507 KB
Event Society of Laboratory Automation & Screening (SLAS) Event